<DOC>
	<DOC>NCT00706797</DOC>
	<brief_summary>To assess comparative radiographic efficacy, clinical efficacy and safety of etanercept (ETN) + methotrexate (MTX) with usual disease-modifying anti-rheumatic drug (DMARD) treatment in subjects with moderate RA who were treated with MTX monotherapy, but continue to have moderate disease activity.</brief_summary>
	<brief_title>Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Meet the 1987 ACR Revised Criteria for Rheumatoid Arthritis. Documented evidence, confirmed by a blinded 3rd party assessor, of at least one erosion observed by Xray at randomization based on Xray taken at the screening visit. Have received MTX as stable dose for 28 days prior to the screening visit. Previous treatment with ETN, infliximab, adalimumab, other Tumor necrosis factor (TNF) a inhibitors, anakinra or other biological agents. Receipt of any DMARD, other than MTX, within 28 days before screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Moderate Rheumatoid Arthritis</keyword>
</DOC>